World Journal of Gastrointestinal Surgery

World J Gastrointest Surg 2023 March 27; 15(3): 307-494





Published by Baishideng Publishing Group Inc

G S WU

World Journal of Gastrointestinal Surgery

Contents

Monthly Volume 15 Number 3 March 27, 2023

MINIREVIEWS

307 Surgical management of acute pancreatitis: Historical perspectives, challenges, and current management approaches

Alzerwi N

- 323 Current trends in perioperative treatment of resectable gastric cancer Yıldız İ, Özer L, Şenocak Taşçı E, Bayoglu İV, Aytac E
- 338 Vascular injury during laparoscopic cholecystectomy: An often-overlooked complication Pesce A, Fabbri N, Feo CV

ORIGINAL ARTICLE

Basic Study

346 Differential expression and significance of 5-hydroxymethylcytosine modification in hepatitis B virus carriers and patients with liver cirrhosis and liver cancer

Li YC, Hu WY, Li CH, Zhang LL, Xu XW, Li J, Luo HX

Retrospective Cohort Study

Compliance with enhanced recovery after surgery predicts long-term outcome after hepatectomy for 362 cholangiocarcinoma

Jongkatkorn C, Luvira V, Suwanprinya C, Piampatipan K, Leeratanakachorn N, Tipwaratorn T, Titapun A, Srisuk T, Theeragul S, Jarearnrat A, Thanasukarn V, Pugkhem A, Khuntikeo N, Pairojkul C, Kamsa-Ard S, Bhudhisawasdi V

374 Pain management in patients with hepatocellular carcinoma after transcatheter arterial chemoembolisation: A retrospective study

Guan Y, Tian Y, Fan YW

Retrospective Study

- 387 Risk factors and prediction model for inpatient surgical site infection after elective abdominal surgery Zhang J, Xue F, Liu SD, Liu D, Wu YH, Zhao D, Liu ZM, Ma WX, Han RL, Shan L, Duan XL
- 398 Percutaneous management in hepatic alveolar echinococcosis: A sum of single center experiences and a brief overview of the literature

Eren S, Aydın S, Kantarci M, Kızılgöz V, Levent A, Şenbil DC, Akhan O

408 Clinical features of acute esophageal mucosal lesions and reflux esophagitis Los Angeles classification grade D: A retrospective study

Ichita C, Sasaki A, Shimizu S

420 Positive correlation between latent Epstein-Barr virus infection and severity of illness in inflammatory bowel disease patients

Wei HT, Xue XW, Ling Q, Wang PY, Zhou WX



Contents

Monthly Volume 15 Number 3 March 27, 2023

Clinical Trials Study

430 Efficacy and outcome of extensive intraoperative peritoneal lavage plus surgery vs surgery alone with advanced gastric cancer patients

Song ED, Xia HB, Zhang LX, Ma J, Luo PQ, Yang LZ, Xiang BH, Zhou BC, Chen L, Sheng H, Fang Y, Han WX, Wei ZJ, Xu AM

Randomized Controlled Trial

440 Endoscopic mucosal resection with double band ligation versus endoscopic submucosal dissection for small rectal neuroendocrine tumors

Huang JL, Gan RY, Chen ZH, Gao RY, Li DF, Wang LS, Yao J

SYSTEMATIC REVIEWS

450 Preoperative risk modelling for oesophagectomy: A systematic review

Grantham JP, Hii A, Shenfine J

META-ANALYSIS

471 Effect of music therapy on chemotherapy-induced nausea and vomiting in gastrointestinal cancer: A systematic review and meta-analysis

Zhong FP, Zhong J, Zhong MY

CASE REPORT

480 Immunotherapy in combination with chemotherapy for Peutz-Jeghers syndrome with advanced cervical cancer: A case report

Hu XC, Gan CX, Zheng HM, Wu XP, Pan WS

488 Xanthogranulomatous inflammation requiring small bowel anastomosis revision: A case report Wang W, Korah M, Bessoff KE, Shen J, Forrester JD



Contents

World Journal of Gastrointestinal Surgery

Monthly Volume 15 Number 3 March 27, 2023

ABOUT COVER

Editorial Board Member of World Journal of Gastrointestinal Surgery, Valeriu Marin Srlin, MD, Professor, Surgical Oncologist, Department of Surgery, University of Medicine and Pharmacy of Craiova, Craiova 200391, Dolj, Romania. vsurlin@gmail.com

AIMS AND SCOPE

The primary aim of World Journal of Gastrointestinal Surgery (WJGS, World J Gastrointest Surg) is to provide scholars and readers from various fields of gastrointestinal surgery with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGS mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal surgery and covering a wide range of topics including biliary tract surgical procedures, biliopancreatic diversion, colectomy, esophagectomy, esophagostomy, pancreas transplantation, and pancreatectomy, etc.

INDEXING/ABSTRACTING

The WJGS is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJGS as 2.505; IF without journal self cites: 2.473; 5-year IF: 3.099; Journal Citation Indicator: 0.49; Ranking: 104 among 211 journals in surgery; Quartile category: Q2; Ranking: 81 among 93 journals in gastroenterology and hepatology; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Rui-Rui Wu; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL	INSTRUCTIONS TO AUTHORS		
World Journal of Gastrointestinal Surgery	https://www.wjgnet.com/bpg/gerinfo/204		
ISSN	GUIDELINES FOR ETHICS DOCUMENTS		
ISSN 1948-9366 (online)	https://www.wjgnet.com/bpg/GerInfo/287		
LAUNCH DATE	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH		
November 30, 2009	https://www.wjgnet.com/bpg/gerinfo/240		
FREQUENCY	PUBLICATION ETHICS		
Monthly	https://www.wjgnet.com/bpg/GerInfo/288		
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT		
Peter Schemmer	https://www.wjgnet.com/bpg/gerinfo/208		
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE		
https://www.wjgnet.com/1948-9366/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242		
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS		
March 27, 2023	https://www.wjgnet.com/bpg/GerInfo/239		
COPYRIGHT	ONLINE SUBMISSION		
© 2023 Baishideng Publishing Group Inc	https://www.f6publishing.com		

© 2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com



S W 0

World Journal of Gastrointestinal Surgery

Submit a Manuscript: https://www.f6publishing.com

World J Gastrointest Surg 2023 March 27; 15(3): 398-407

DOI: 10.4240/wjgs.v15.i3.398

Retrospective Study

ISSN 1948-9366 (online)

ORIGINAL ARTICLE

Percutaneous management in hepatic alveolar echinococcosis: A sum of single center experiences and a brief overview of the literature

Suat Eren, Sonay Aydın, Mecit Kantarci, Volkan Kızılgöz, Akın Levent, Düzgün Can Şenbil, Okan Akhan

Specialty type: Radiology, nuclear medicine and medical imaging

Provenance and peer review: Unsolicited article; Externally peer reviewed

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): B, B Grade C (Good): 0 Grade D (Fair): 0 Grade E (Poor): 0

P-Reviewer: Corrales FJ, Spain; Tavan H, Iran

Received: November 24, 2022 Peer-review started: November 24, 2022 First decision: December 10, 2022 Revised: December 18, 2022

Accepted: February 14, 2023 Article in press: February 14, 2023 Published online: March 27, 2023



Suat Eren, Department of Radiology, Faculty of Medicine, Atatürk University, Erzurum 25100, Turkey

Sonay Aydın, Mecit Kantarci, Volkan Kızılgöz, Akın Levent, Düzgün Can Şenbil, Department of Radiology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey

Okan Akhan, Department of Radiology, Hacettepe University, Ankara 06090, Turkey

Corresponding author: Düzgün Can Şenbil, MD, Academic Research, Doctor, Research Assistant, Department of Radiology, Faculty of Medicine, Erzincan Binali Yıldırım University, Hacı Ali akın Street, Erzincan 24100, Turkey. senbilcan@gmail.com

Abstract

BACKGROUND

Hepatic alveolar echinococcosis (HAE) is a serious zoonotic infection that affects humans. It may have a tumor-like appearance at times. Percutaneous treatment of HAE patients is extremely relaxing for them. HAE is a significant human zoonotic infection caused by the fox tapeworm Echinococcus Multilocularis larvae. It possesses the characteristics of an invasive tumor-like lesion due to its infiltrative growth pattern and protracted incubation period. The disease is endemic over central Europe, Asia, and North America.

AIM

To characterize HAE patients who were treated percutaneously, their outcomes, and the major technical features of percutaneous treatment in HAE.

METHODS

Patients who were treated with percutaneous cyst drainage and/or percutaneous biliary drainage were included in the study. Uncorrected abnormal coagulation values and solid or non-infected HAE with minor necrotic change were excluded.

RESULTS

Thirty-two patients underwent percutaneous cyst drainage, two patients underwent percutaneous biliary drainage, and four patients underwent percutaneous biliary drainage alone. Interventional radiology is utilized to drain echinococcal necrosis and abscesses within/without the liver, as well as diseased



WJGS | https://www.wjgnet.com

and clogged bile ducts.

CONCLUSION

Percutaneous drainage of cyst contents and/or biliary channels using a minimally invasive technique is a very beneficial. Percutaneous cyst drainage with albendazole therapy improves quality of life in patients who are unable to undergo surgery, even when the mass resolves with long-term treatment.

Key Words: Interventional; Radiology; Treatment; Alveolar echinococcosis; Liver

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Interventional radiology is utilized to drain echinococcal necrosis and abscesses within/without the liver either as palliative operations or as a bridge to radical resection. Percutaneous cyst drainage with albendazole therapy improves quality of life in patients who are unable to undergo surgery, even when the mass resolves with long-term treatment.

Citation: Eren S, Aydın S, Kantarci M, Kızılgöz V, Levent A, Şenbil DC, Akhan O. Percutaneous management in hepatic alveolar echinococcosis: A sum of single center experiences and a brief overview of the literature. *World J Gastrointest Surg* 2023; 15(3): 398-407

URL: https://www.wjgnet.com/1948-9366/full/v15/i3/398.htm DOI: https://dx.doi.org/10.4240/wjgs.v15.i3.398

INTRODUCTION

Hepatic alveolar echinococcosis (HAE) is a significant human zoonotic infection caused by the fox tapeworm *Echinococcus Multilocularis* larvae (EM). It possesses the characteristics of an invasive tumor-like lesion due to its infiltrative growth pattern and protracted incubation period. The disease is endemic over central Europe, Asia, and North America[1,2].

Percutaneous sterilization procedures, surgery, medication treatment, a "wait-and-see" approach, or a combination of these are available for management. In comparison, the clinical signs of alveolar echinococcosis (AE) are similar to those of a malignant, silently progressive liver disease, with local tissue infiltration and metastasis. Structured treatment is critical for AE management, which involves WHO staging, pharmacological therapy, and at least a decade of follow-up[3].

While excision of lesions or liver transplantation (LT) is the most successful treatment option when operable, the majority of patients require palliative care prior to open surgery due to the presence of comorbidities. Typically, the disease is identified at an irreversible stage. In certain instances, invasion of the bile ducts and arteries, as well as necrosis in the lesion's center, result in serious consequences such as cholangitis and liver abscesses. Palliative surgery has been shown to have little advantage in terms of care, while percutaneous and endoscopic techniques have increased in popularity. In these patients, percutaneous draining of the complex cyst and biliary tree may be employed as a minimally invasive technique[2,4-6].

The purpose of this study is to characterize the methods to treat HAE patients, the outcomes of the treatment options, and the major technical features of percutaneous treatment in HAE.

MATERIALS AND METHODS

Patients and diagnosis

Electronic archives were retrospectively evaluated to define the treatment options of the HAE patients between January 2012-December 2021. Patients were classified under two main subgroups: (1) surgical treatment: complete surgical excision and antihelmintic therapy, partial resection and antihelmintic therapy, LT; and (2) Interventional radiologic treatment: percutaneous cyst drainage, percutaneous cyst drainage only.

The first diagnosis was made mostly on the basis of conventional imaging findings such as computed tomography (CT) scans in three phases (hepatic artery, portal vein, and hepatic vein); ultrasound (US); immunoserologic testing with enzyme-linked immunosorbent assay; and, in some cases, magnetic resonance imaging (MRI).

WJGS | https://www.wjgnet.com

Age, gender data and the presence/frequency of the complications were noted.

Interventional radiologic treatment: Uncorrected abnormal coagulation values and solid or noninfected HAE with minor necrotic change were the main contraindications for interventional radiologic treatment. The big necrotic cyst or infected cyst with or without mass effect on the biliary tree and surrounding arteries were the selection criteria for percutaneous cyst drainage.

All cases were reviewed for percutaneous access to the cyst, application route, and selection of the appropriate imaging modality for guidance prior to draining. Generally, we preferred US entry advice. We chose CT guidance for cysts that were difficult to visualize with US (due to thick calcification of the cyst wall or conspicuous gas within the cyst). Patients with abnormal coagulation parameters were handled as soon as possible after hematologic correction. In situations of cholangitis or biliary obstruction due to mass invasion, percutaneous biliary drainage was performed. Seldinger's method was used to install drainage catheters (8-10 Fr). We employed both intercostal and subcostal techniques.

Statistical analysis

The Statistical Package for Social Sciences for Windows 20 software was used to analyze the data (IBM SPSS Inc., Chicago, IL, United States). The Kolmogorov-Smirnov test was used to determine whether the data conformed to a normal distribution. Numerical variables with a normal distribution were represented as mean \pm SD values and categorical variables as number (*n*) and percentage values (%). Age was compared across groups using the student's t test, and the frequency of complications was analyzed using the Chi-square test according to subgroups.

RESULTS

Patients

The current study included 125 patients, 67 (53.6%) of whom were female and 58 (46.4%) of whom were male. Mean age of the population was 53.6 ± 8.4 years, median age was 63 years (min-max; 41-82 years). Table 1 shows the detailed distribution of patients based on treatment options.

Surgical treatment

Mean age of the patients was 48.8 ± 3.4 years. 45 patients (51.7%) were female and 42 (48.2%) patients were male.

Complications were discovered in 15 (17.2%) patients: Fever (8 patients), hemorrage (4 patients), subphrenic infection (2 patient), bile leakage (1 patient).

Figures 1 and 2 demonstrate the significant radiologic findings of surgically treated patients.

Interventional radiologic treatment

Mean age of the patients was 64.5 ± 6.1 years, 20 patients (52.6%) were female and 18 (47.3%) patients were male.

Twenty-eight lesions mostly located in the right lobe (73.6 %) and 9 lesions primarily located in the left lobe (32.1%). There was bilateral involvement in one case (2.6%). Cyst infection was detected at 11 (28.9%) cases.

Intercostal route was used in six patients (15.7 %), whereas subcostal approach was preferred in the rest. All cysts were effectively drained, and no significant complications associated with catheter drainage were observed during follow-up. Complication rate was significantly higher in surgical treatment group than interventional radiologic treatment (P = 0.001). Catheters were replaced due to blockage or stenosis in six patients. All patients admitted prophylactic antibiotics and albendazole.

Figure 3 demonstrates the significant findings of interventional radiologic treatment. Table 2 contains further information about the patients covered.

Extrahepatic findings

There were no cases of extrahepatic alveolar echinococcosis in the surgical therapy group. Whereas, in the interventional radiologic treatment subgroup, six patients were diagnosed with extrahepatic alveolar echinococcosis: three in the lung, one in the adrenal gland, one in the brain (Figure 4), and one in the peritoneal cavity.

DISCUSSION

Alveolar echinococcosis is one of the most dangerous and potentially fatal zoonoses on the planet, and it appears to be spreading across Europe[1,7]. In 97 percent of patients, lesions begin in the liver. Due to the larva's slow growth rate, it behaves similarly to a slow-growing invasive tumor that eventually invades the liver parenchyma, arteries, and bile ducts. In severe HAE, the mass may invade all neighboring organs and spread hematogenously to distant organs such as the lungs and brain[8,9].



Table 1 Distribution of patients based on treatment options, n (%)							
Surgical treatment		Interventional radiologic treatment					
Complete surgical excision and antihelmintic therapy	60 (48)	Percutaneous cyst drainage	32 (25.6)				
Partial resection and antihelmintic therapy	23 (18.4)	Percutaneous cyst drainage with percutaneous biliary drainage	2 (1.6)				
Liver transplantation	4 (3.2%)	Percutaneous biliary drainage only	4 (3.2)				
Total	87 (69.6)	Total	38 (30.4)				



DOI: 10.4240/wjgs.v15.i3.398 Copyright ©The Author(s) 2023.

Figure 1 Male, 28 years old. Hepatic alveolar echinococcosis is a serious infection that requires liver replacement. A: On axial portal venous phase contrast enhanced computed tomography, a large cystic mass is visible; B: After percutaneous treatment, the lesion's size has decreased, and a drainage catheter is visible (arrow); C: Percutaneous drainage was unable to heal the lesion, and liver transplantation was undertaken.



DOI: 10.4240/wjgs.v15.i3.398 Copyright ©The Author(s) 2023.

Figure 2 Female, 50-year-old. Treatment of hepatic alveolar echinococcosis with right hepatectomy. A: On axial portal venous phase contrast enhanced computed tomography, a large cystic mass is visible; B: After percutaneous treatment, the lesion's size has decreased, and a drainage catheter is visible (arrow); C: Percutaneous drainage was unable to heal the condition, and a right hepatectomy was performed.

> There are studies in the literature that show that familial factors may influence susceptibility to alveolar echinococcosis[10]. However, family clustering is extremely uncommon in alveolar echinococcus. The rate of blood ties between patients was found to be 13% in a study of 153 people. As a result, in the event of alveolar echinococcosis, the family should be screened with US[11].

> Immunoserologic studies based on the use of EM are useful in diagnosing and determining the EM agent. In the United States, HAE lesions frequently present as ill-defined heterogeneous infiltrations. While necrosis and infection cause hypoechoic foci inside the mass, hyperechoic zones are associated with fibro-parasitic tissue and dispersed calcifications. CT demonstrates the invading mass's characteristic calcifications more clearly. Triphasic contrast enhanced CT imaging is very beneficial for determining the vascular and biliary extension and invasion of neighboring tissue. With its high sensitivity to soft tissue, MRI is extremely useful for detecting satellite liver lesions, invasions, and central nervous system lesions, as well as examining the biliary tract[12].

> Due to the sluggish growing rate of cysts, there is typically an asymptomatic phase before diagnosis of several years. The clinical appearance is similar to that of slow-growing liver cancer, and severe illness almost always involves invasion of the biliary and vascular walls. Although it is always fatal if not properly treated, early detection and treatment offer a better prognosis[13,14].

> Although radical liver resection is the preferred method of treatment in order to prevent palliative surgical procedures, total excision of the mass is frequently not possible. LT should be regarded as a viable option for life-saving treatment. LT, on the other hand, is not always feasible and is contrain-



WJGS | https://www.wjgnet.com

Table 2 Details of the included patients								
No.	Age/gender	Location of cyst	Cystic content	Percutaneous treatment	Surgery			
1	35/M	RL	Infected PD		LT			
2	47/F	LL	Non-infected	PD	No			
3	58/F	RL	Non-infected	PD-PBD	No			
4	60/F	LL	Non-infected	PD	No			
5	37/M	RL	Non-infected	PD	Right lobectomy			
6	66/F	RL	Non-infected	PD	No			
7	33/F	RL	Non-infected	PD	LT			
8	36/F	RL	Non-infected	PD	LT			
9	36/M	RL	Non-infected	PD	LT			
10	52/F	RL	Infected	PD-PBD	LT			
11	57/M	RL	Non-infected	PD	LT			
12	33/F	RL	Infected	PD	Right lobectomy			
13	26/F	RL	Infected	PD	Right lobectomy			
14	62/M	RL	Non-infected	PD	No			
15	39/M	LL	Infected	PD	No			
16	59/M	LL	Non-infected	PD	No			
17	66/F	LL	Non-infected	PD	No			
18	21/F	LL	Infected	PD	Left lobectomy			
19	24/M	RL	Non-infected	PD	LT			
20	35/M	RL	Non-infected	PD	LT			
21	51/M	RL	Non-infected	PD	Right lobectomy			
22	44/F	RL	Non-infected	PD	No			
23	28/M	RL	Infected	PD	LT			
24	57/F	RL	Non-infected	PD	LT			
25	71/F	RL	Non-infected	PD	No			
26	17/M	RL	Non-infected	PD	No			
27	39/F	RL	Non-infected	PD	No			
28	71/F	RL	Infected	PD	No			
29	50/F	RL	Infected	PD	Right lobectomy			
30	34/M	Bilateral	Non-infected	PD	No			
31	28/M	RL	Non-infected	PD	No			
32	50/M	LL	Non-infected	PD	Left lobectomy			
33	15/M	LL	Infected	PD	Inoperable			
34	61/M	RL	Infected	PD	Inoperable			
35	45/F	LL	Non-infected	PBD	No			
36	53/F	RL	Non-infected	PBD	LT			
37	25/F	RL	Non-infected	PBD	LT			
38	43/F	RL	Non-infected	PBD	LT			

PD: Percutaneous drainage of cyst; PBD: Percutaneous biliary drainage; RL: Right lobe of liver; LL: Left lobe of liver; M: Male; F: Female.

Raisbideng® WJGS | https://www.wjgnet.com



DOI: 10.4240/wjgs.v15.i3.398 Copyright ©The Author(s) 2023.

Figure 3 Female, 32-year-old. A: Alveolar Echinococcosis at right liver lobe, with typical peripheral calcifications and large central necrosis; B: 3D image in the coronal plane illustrates the location of the percutaneous drainage catheter and the external biliary drainage catheter in the patient; C: Drainage catheter can be seen in within the lesion (arrow); D: The shrunken lesion cavity and the regression of the dilatation in the left intrahepatic bile ducts are illustrated by 3D coronal plane image. PDC: Percutaneous drainage catheter; IVC: Inferior vena cava; EBDC: External biliary drainage catheter; LHV: Left hepatic vein; RHD: Right hepatic duct; LHD: Left hepatic duct; CHA: Common hepatic artery; HPV: Hepatic portal vein; CBD: Common biliary duct; Gb: Gallbladder; CD: Cystic duct.



DOI: 10.4240/wjgs.v15.i3.398 Copyright ©The Author(s) 2023.

Figure 4 Male, 45 years old. A and B: Axial magnetic resonance imaging demonstrates enhancing brain lesions associated with alveolar echinococcosis (circles). Alveolar Echinococcosis is also prevalent in the parenchyma of the left lung (arrow); C: Percutaneous drainage was performed; typical calcifications (white arrow) are visible, as is the drainage catheter (black arrow); D: 3D axial plane cross sectional illustration image shows the percutaneous drainage catheter placement in the lesion cavity. PDC: Percutaneous drainage catheter; IVC: Inferior vena cava; Ao: Abdominal aorta; IVC: Inferior vena cava; St: Stomach; Sp: Spleen.

dicated in patients with residual or metastatic HAE[15,16]. Depending on the degree of liver surgery, documented complication rates ranged from 15% to 36%, and fatality rates after excision ranged from 3% to 4.2%[17]. Similarly to the literature, the complication rate of surgical treatment in our sample was 17.2%, but we identified no issues in the interventional radiologic treatment subgroup, despite having a higher mean age. This suggests that interventional radiological therapy may be a viable treatment option for alveolar echinococcosis.

Baishidena® WJGS | https://www.wjgnet.com

Despite all major surgical procedures, only half of the patients recovered completely. Interventional radiological treatments have been developed over time and have replaced palliative surgeries[18,19]. Drugs that inhibit parasitic growth are also crucial in the treatment of alveolar echinococci. In a series of 37 patients, Bresson-Hadni *et al*[14] used a multidisciplinary approach. In comparison to the past, only one patient received a liver transplant, and palliative surgery rates dropped by 80% in the literature.

HAE lesions are divided into three types: solid, pseudocystic, and mixed. While percutaneous cyst drainage can be performed in pseudocystic and mixed forms, percutaneous biliary drainage can be performed in any form as a palliative treatment for biliary stasis[20].

Cyst enlargement may result in compression or obstruction of the circulatory and biliary systems. Cyst necrosis and infection are two primary factors that contribute to fast cyst growth. The mass's inadequate vascularization frequently results in necrosis in the center portion of the lesion. Necrosis increases the intra-cystic pressure and mass effect, which may result in biliary stasis, cysto-biliary fistula, or necrotic cyst content rupture into the peritoneal and/or pleural space. With lower intracystic pressure, catheter drainage of necrotic material minimizes these problems[21].

Cyst infection is a significant consequence of HAE and may present acutely as cholangitis and septicemia, mimicking a liver abscess. Catheter drainage of infected cysts, such as liver abscess, should be performed until favorable conditions for major surgery are achieved. Because surgical therapy is contraindicated in acutely infected cysts, transcatheter drainage of a life-threatening bacterial or fungal infection within the cyst may be performed as a bridge operation in symptomatic patients prior to a curative surgical procedure. Catheter drainage can alleviate both the symptoms associated with abscess and the compressive symptoms on the arteries and biliary tree[8,21]. Eleven of our patients with infected cystic content were successfully treated with drainage.

In cases of infectious manifestations of centro-parasitic abscess or cholangitis, radiological interventional procedures are extremely useful. Percutaneous drainage of massive centro-parasitic abscesses, combined with systemic antibiotics, significantly improves the patient's clinical status. It is especially useful in elderly patients for whom a partial hepatectomy is not an option. Radiological interventional procedures are also very helpful in cases of cholangitis caused by parasitic tissue infiltration of the biliary tree and the resulting fibro-inflammatory reaction[22].

Biliary blockage symptoms typically emerge as a result of direct invasion of the major bile ducts or as a result of HAE's mass effect. Cholangitis symptoms may also be present as a result of parasite mass connection with bile ducts or pigment stones accumulating above a parasitic biliary stenosis[8]. Biliary blockage and cholangitis result in a more rapid decline in liver function, as well as mass destruction of the liver tissue. In these instances, if the patient has a large necrotic mass, we choose cyst drainage to alleviate tension on the biliary tree and major arteries. In certain cases, biliary stasis symptoms may improve with cyst draining alone due to the cyst's reduction in size. If biliary invasion and extensive cysto-biliary fistulas are present, the bile content of the cyst can be drained concurrently with the cyst content without extra biliary drainage. If these individuals benefit just from cyst drainage, this approach may be beneficial in avoiding the use of several catheters and may be sufficient in the interim till surgery. If patients have not demonstrated sufficient benefit from cyst draining, catheterization of one or two sides of the biliary tree should alleviate symptoms of biliary stasis.

In patients who are unable to undergo surgery, percutaneous cyst drainage and/or percutaneous biliary drainage with albendazole medication are the only treatment options available to protect these patients from re-infection, rupture, and to alleviate compressive symptoms. Biliary stenting may be combined with percutaneous biliary drainage or cyst draining if necessary[2]. We also have examples extrahepatic alveolar echinococcosis. Percutaneous cyst draining was used to treat one incidence of metastases to peritoneal cavity due to infected cystic material. Another case with cerebral metastases was treated with percutaneous draining of the infected cyst and albendazole (10 mg/kg) medical treatment. Extrahepatic involvement was not uncommon in patients treated with interventional radiologic procedures, according to our patient sample. The relevance of the radiologic workup before deciding on the sort of treatment is highlighted at this point. Extensive exams for extrahepatic involvement, particularly with CT or MRI, can aid in determining the best course of treatment.

Although percutaneous drainage is extremely beneficial in HAE patients, our cases had certain restrictions. Transcatheter draining of alveolar cysts is more challenging than conventional cyst drainage. To begin, we generally opted to apply US instructions. Nonetheless, the cyst's appearance was obscured in some cases due to significant calcification or strong fibrosis. In some patients, CT guidance for needle entry and catheter placement may be required. Second, the cyst capsule proved difficult to puncture due to its rigid nature. As a result, we are required to employ a thick needle for entrance and to dilate the tract prior to catheter drainage installation. Prior to catheter implantation, it is beneficial to lower positive pressure within the cyst *via* cystic content aspiration to minimize peritoneal seeding in these circumstances. Nonetheless, catheter exchange is required in the majority of patients undergoing follow-up.

Zaishideng® WJGS | https://www.wjgnet.com

CONCLUSION

Interventional radiology is utilized to drain echinococcal necrosis and abscesses within/without the liver, as well as diseased and clogged bile ducts, in HAE cases, either as palliative operations or as a bridge to radical resection. These techniques not only relieve pressure on the hepatic arteries and biliary path, but also make surgical resection easier by minimizing peripheral granulation tissue. In acutely infected patients, percutaneous drainage of cyst contents and/or biliary channels using a minimally invasive technique is a very beneficial, if not required, surgery that can save lives in some circumstances. Percutaneous cyst drainage with albendazole therapy improves quality of life in patients who are unable to undergo surgery, even when the mass resolves with long-term treatment.

ARTICLE HIGHLIGHTS

Research background

Alveolar echinococcus is a zoonotic infection that can be fatal in humans. In our study, we conducted a brief assessment of the role of interventional radiology in the treatment of alveolar echinococcus.

Research motivation

Despite radical surgical procedures, the rate of complete recovery from alveolar echinococcus is quite low. Patients can benefit greatly from an increase in the success rates of treatments performed with interventional radiology.

Research objectives

The goal of our research is to compare the success rates of interventional radiological methods to surgical methods.

Research methods

Our clinic's experience and those mentioned in the literature, as well as surgical methods, were compared.

Research results

Interventional radiology can be used to treat infected alveolar echinococci in particular.

Research conclusions

Interventional radiology can be used to treat infected alveolar echinococci in particular. Palliative surgery rates may thus fall.

Research perspectives

In our study, it was aimed to provide convenience for the patient and save time and money by advancing interventional radiological treatment methods in the treatment of alveolar echinococcus.

FOOTNOTES

Author contributions: Eren S, Aydın S and Kantarcı M contributed with data acquisition; Kızılgöz V performed the statistical analysis; Levent A, Senbil DC and Akhan O contributed to study design; Eren S and Kızılgöz V contributed to critical analysis; Senbil DC and Aydın S contributed to writing and critical review of the manuscript; All authors read and approved the final manuscript.

Institutional review board statement: The Ethics and Research Board of the Erzincan Binali Yıldırım University faculty of medicine approved the study, No. EBYU-KAEK-2020-001-297.

Informed consent statement: Written informed consent was obtained from the participants.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Data sharing statement: Data used in this study is available from the corresponding author on reasonable request.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/



Country/Territory of origin: Turkey

ORCID number: Sonay Aydın 0000-0002-3812-6333; Mecit Kantarci 0000-0002-1043-6719; Düzgün Can Şenbil 0000-0003-0233-7371.

S-Editor: Zhang H L-Editor: A P-Editor: Zhang H

REFERENCES

- Romig T, Deplazes P, Jenkins D, Giraudoux P, Massolo A, Craig PS, Wassermann M, Takahashi K, de la Rue M. Ecology and Life Cycle Patterns of Echinococcus Species. Adv Parasitol 2017; 95: 213-314 [PMID: 28131364 DOI: 10.1016/bs.apar.2016.11.002
- Kantarci M, Bayraktutan U, Karabulut N, Aydinli B, Ogul H, Yuce I, Calik M, Eren S, Atamanalp SS, Oto A. Alveolar echinococcosis: spectrum of findings at cross-sectional imaging. Radiographics 2012; 32: 2053-2070 [PMID: 23150858 DOI: 10.1148/rg.327125708]
- 3 Kern P, Menezes da Silva A, Akhan O, Müllhaupt B, Vizcaychipi KA, Budke C, Vuitton DA. The Echinococcoses: Diagnosis, Clinical Management and Burden of Disease. Adv Parasitol 2017; 96: 259-369 [PMID: 28212790 DOI: 10.1016/bs.apar.2016.09.006
- 4 Bulakçı M, Kartal MG, Yılmaz S, Yılmaz E, Yılmaz R, Şahin D, Aşık M, Erol OB. Multimodality imaging in diagnosis and management of alveolar echinococcosis: an update. Diagn Interv Radiol 2016; 22: 247-256 [PMID: 27082120 DOI: 10.5152/dir.2015.15456]
- Dagoglu-Kartal MG, Ciftci T, Ozer C, Akinci D, Akhan O. Case Report: Role of Interventional Radiology in the Management of Patients with Alveolar Echinococcus: Successful Management of Three Cases. Am J Trop Med Hyg 2018; 98: 1403-1407 [PMID: 29611496 DOI: 10.4269/ajtmh.17-0089]
- 6 Koroglu M, Akhan O, Gelen MT, Koroglu BK, Yildiz H, Kerman G, Oyar O. Complete resolution of an alveolar echinococcosis liver lesion following percutaneous treatment. Cardiovasc Intervent Radiol 2006; 29: 473-478 [PMID: 16228851 DOI: 10.1007/s00270-005-0017-0]
- 7 Brehm K. The role of evolutionarily conserved signalling systems in Echinococcus multilocularis development and hostparasite interaction. Med Microbiol Immunol 2010; 199: 247-259 [PMID: 20376483 DOI: 10.1007/s00430-010-0154-1]
- Bresson-Hadni S, Miguet JP, Mantion G, Giraudoux P, Vuitton DA. L'échinococcose alvéolaire: une maladie comparable à un cancer du foie à marche lente [Alveolar echinococcosis: a disease comparable to a slow growing cancer]. Bull Acad Natl Med 2008; 192: 1131-1138 [PMID: 19235477]
- Moray G, Shahbazov R, Sevmis S, Karakayali H, Torgay A, Arslan G, Savas N, Yilmaz U, Haberal M. Liver transplantation in management of alveolar echinococcosis: two case reports. Transplant Proc 2009; 41: 2936-2938 [PMID: 19765480 DOI: 10.1016/j.transproceed.2009.07.022]
- 10 Vuitton DA, Zhang SL, Yang Y, Godot V, Beurton I, Mantion G, Bresson-Hadni S. Survival strategy of Echinococcus multilocularis in the human host. Parasitol Int 2006; 55 Suppl: S51-S55 [PMID: 16360335 DOI: 10.1016/j.parint.2005.11.007]
- Yang YR, Ellis M, Sun T, Li Z, Liu X, Vuitton DA, Bartholomot B, Giraudoux P, Craig PS, Boufana B, Wang Y, Feng X, 11 Wen H, Ito A, McManus DP. Unique family clustering of human echinococcosis cases in a chinese community. Am J Trop Med Hyg 2006; 74: 487-94 [PMID: 16525111]
- Bresson-Hadni S, Delabrousse E, Grenouillet F, Mantion G, Vuitton DA. [Alveolar echinococcosis: how to confirm the 12 diagnosis? Bull Acad Natl Med 2008; 192: 1141-1149 [PMID: 19235478]
- Piarroux M, Piarroux R, Giorgi R, Knapp J, Bardonnet K, Sudre B, Watelet J, Dumortier J, Gérard A, Beytout J, Abergel 13 A, Mantion G, Vuitton DA, Bresson-Hadni S. Clinical features and evolution of alveolar echinococcosis in France from 1982 to 2007: results of a survey in 387 patients. J Hepatol 2011; 55: 1025-1033 [PMID: 21354448 DOI: 10.1016/j.jhep.2011.02.018
- 14 Bresson-Hadni S, Delabrousse E, Blagosklonov O, Bartholomot B, Koch S, Miguet JP, Mantion GA, Vuitton DA. Imaging aspects and non-surgical interventional treatment in human alveolar echinococcosis. Parasitol Int 2006; 55 Suppl: S267-S272 [PMID: 16403670 DOI: 10.1016/j.parint.2005.11.053]
- Kawamura N, Kamiyama T, Sato N, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Yamaga S, Matsushita M, Todo S. 15 Long-term results of hepatectomy for patients with alveolar echinococcosis: a single-center experience. J Am Coll Surg 2011; 212: 804-812 [PMID: 21398158 DOI: 10.1016/j.jamcollsurg.2011.02.007]
- 16 Vuitton DA, Bresson-Hadni S, Giraudoux P, Bartholomot B, Laplante JJ, Delabrousse E, Blagosklonov O, Mantion G. [Alveolar echinococcosis: from an incurable rural disease to a controlled urban infection]. Presse Med 2010; 39: 216-230 [PMID: 19423275 DOI: 10.1016/j.lpm.2008.10.028]
- Salm LA, Lachenmayer A, Perrodin SF, Candinas D, Beldi G. Surgical treatment strategies for hepatic alveolar 17 echinococcosis. Food Waterborne Parasitol 2019; 15: e00050 [PMID: 32095621 DOI: 10.1016/j.fawpar.2019.e00050]
- 18 Bresson-Hadni S, Vuitton DA, Bartholomot B, Heyd B, Godart D, Meyer JP, Hrusovsky S, Becker MC, Mantion G, Lenys D. Miguet JP. A twenty-year history of alveolar echinococcosis: analysis of a series of 117 patients from eastern France. Eur J Gastroenterol Hepatol 2000; 12: 327-336 [PMID: 10750654 DOI: 10.1097/00042737-200012030-00011]
- Roche G, Canton P, Gerard A, Colin D, Boissel P, Chaulieu C, Dureux JB. Essai de traitement de l'échinococcose alvé olaire par le flubendazole. A propos de 7 observations. Med Mal Infect 1982; 12: 218-230 [DOI: 10.1016/s0399-077x(82)80036-x]



- 20 Liu YH, Wang XG, Gao JS, Qingyao Y, Horton J. Continuous albendazole therapy in alveolar echinococcosis: long-term follow-up observation of 20 cases. Trans R Soc Trop Med Hyg 2009; 103: 768-778 [PMID: 19457528 DOI: 10.1016/j.trstmh.2009.04.006]
- 21 Matsumoto J, Yagi K. Experimental studies on Echinococcus multilocularis in Japan, focusing on biohazardous stages of the parasite. Exp Parasitol 2008; 119: 534-541 [PMID: 18396283 DOI: 10.1016/j.exppara.2008.02.008]
- 22 Vuitton DA, Mantion G, Million L, Bresson-Hadni S. [Échinococcose alvéolaire]. Rev Prat 2020; 70: 754-764 [PMID: 33739723]





Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: bpgoffice@wjgnet.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

